Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in Relapsed/Refractory B-Cell Lymphoma
NCT00446095Phase 2Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Apr 2007
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fostamatinib in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), mucosa associated lymphoid tissue lymphoma, marginal zone lymphoma (MZL), sponsored by Rigel Pharmaceuticals, Inc.. Started Apr 2007; status: completed.
02
Drugs
fostamatinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)mucosa associated lymphoid tissue lymphomamarginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT00446095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00446095.